KALA רווח נקי למניה (EPS TTM) KALA BIO, Inc.

Analyzing the change in rolling net income per share for KALA BIO, Inc. (KALA) on GURU.Markets, we note that the latest figure stands at -73.54, confirming a liquidity deficit driven by R&D expenditures. KALA BIO, Inc. (KALA) attracts ophthalmology scientists through options and grants, while outsourcing manufacturing and clinical operations to third-party contractors to optimize marketing. This approach enables a strategic focus on innovations in eye treatment.
פילוחי נתונים אנליטיים מרוכזים עבור KALA BIO, Inc. (KALA)

KALA BIO, Inc. (KALA) maintains a monopoly status in ophthalmology due to its patents for overcoming the mucus barrier, creating potential for high business margins. Analyzing this 12-month EPS chart, an investor can see real earnings per share stripped of paper revaluations and issuance fluctuations, allowing for an objective assessment of value accumulation and the long-term capital stability of the company.